Myotonic Dystrophy Clinical Trials in Richmond, Virginia
8 recruitingRichmond, Virginia
Showing 1–8 of 8 trials
Recruiting
Phase 1Phase 2
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1
Myotonic Dystrophy
Sanofi32 enrolled9 locationsNCT06844214
Recruiting
Phase 1Phase 2
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics116 enrolled17 locationsNCT05481879
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
Myotonic Dystrophy Type 1 (DM1)
Vertex Pharmaceuticals Incorporated44 enrolled26 locationsNCT06185764
Recruiting
Phase 1Phase 2
Study of ATX-01 in Participants With DM1
Myotonic Dystrophy 1
ARTHEx Biotech S.L.56 enrolled12 locationsNCT06300307
Recruiting
Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
Myotonic DystrophyCongenital Myotonic DystrophyChildhood Myotonic Dystrophy
Virginia Commonwealth University200 enrolled1 locationNCT06747884
Recruiting
DMCRN-02-001: Assessing Pediatric Endpoints in DM1
Congenital Myotonic DystrophyCDM
Virginia Commonwealth University50 enrolled5 locationsNCT05224778
Recruiting
Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Myotonic Dystrophy 1DM1
Virginia Commonwealth University700 enrolled17 locationsNCT03981575
Recruiting
Phase 2Phase 3
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Congenital Myotonic Dystrophy
AMO Pharma Limited76 enrolled14 locationsNCT05004129